Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

January 30, 2027

Conditions
Infertility
Interventions
DRUG

Recombinant Human Follitropin Alfa Solution for Injection (Gonal-f®)

As a r-hFSH agent, Gonal-f® is used for COS. It is a prefilled ready to use pen device containing follitropin alfa for injection and is designed for subcutaneous self-administration by patients undergoing COS for ART. It is available as dose presentations of 150 IU and 450 IU. The investigators and/or his/her delegate/s will explain the use of Gonal-f® prefilled pen. Gonal-f® will be prescribed by the investigator based on clinical diagnosis and treatment routines, and will not be provided free of charge.

DRUG

Recombinant Human Lutropin alfa for Injection (r-hLH, Luveris®)

This product is a white freeze-dried powder and a colorless and clear injection solvent, and stored away from light under 25℃ in the original packaging. Luveris® will be provided free of charge.

Trial Locations (1)

210008

Nanjing Drum Tower Hospital, Nanjing

All Listed Sponsors
lead

Nanjing University

OTHER

NCT06571214 - Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment | Biotech Hunter | Biotech Hunter